Chemotherapy
VS Immunotherapy

OVERVIEW

So, What Is The Difference?

For starters, chemotherapy acts directly on cancerous tumours, whereas
immunotherapy actually treats patients by acting on their immune system.

Chemotherapy

https://immunotherapy.life/wp-content/uploads/2021/02/Diagram-Chemo-Immunotheraphy-01.png

Immunotherapy

Unleashes the patient’s own immune system

https://immunotherapy.life/wp-content/uploads/2021/02/Diagram-Chemo-Immunotheraphy-02.png
https://immunotherapy.life/wp-content/uploads/2021/02/Icon-1-1.png
https://immunotherapy.life/wp-content/uploads/2021/02/Icon-1-1.png

Side Effects

Chemotherapy: Side effects result from drugs attacking both cancerous and non-cancerous cells.

Immunotherapy: Side effects result from an overstimulated or misdirected immune response.

https://immunotherapy.life/wp-content/uploads/2021/02/Icon-2-1.png
https://immunotherapy.life/wp-content/uploads/2021/02/Icon-2-1.png

Post Treatment Protection

Chemotherapy: Its effect lasts as long as the drugs remain in the body.

Immunotherapy: Provides long-term protection against cancer, due to the immune system’s ability to recognise and remember what cancer cells look like.

https://immunotherapy.life/wp-content/uploads/2021/02/Icon-3-1.png
https://immunotherapy.life/wp-content/uploads/2021/02/Icon-3-1.png

Length Of Treatment

Chemotherapy: Typically requires multiple cycles over several months/years.

Immunotherapy: Cell-based immunotherapies (e.g. CAR T-Cell) typicallyonly require a single injection, although some immunotherapies mayrequire several injections.

FAQ

Have Questions About The Process?
We’ve Got You Covered

Chemotherapy VS Immunotherapy FAQ

  • Who Is Eligible For CAR T-Cell Immunotherapy?

    Patients must meet the following criteria to be eligible for CAR T-Cell Immunotherapy:
    • Patient is well enough to receive CAR T-Cell Immunotherapy.
    • Tumour has expressed the appropriate marker, e.g. CD19.
    • An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    • Absence of disease complications or chemo-toxicity; such as, infection, active GVHD, hyperleucocytosis, severe extra medullary disease.
    • Last dose of chemotherapy and/or steroid is at least 2 weeks prior; when in doubt, a T-Cell activation test will be performed.
    • Patient’s tumour burden is as low as possible. In patients with uncontrolled or accelerating tumour burden, induction chemotherapy should be performed first (apheresis should be done prior to commencing the chemotherapy).

  • What Are The Possible Side Effects Of CAR T-Cell Immunotherapy?

    • Cytopenia – Cytopenia occurs when one or more of the blood cell types are lower than it should be. Blood consists of red blood cells which carry oxygen and nutrients around the body, and white blood cells which fight infection.
    • B-Cell Aplasia – B-Cell aplasia occurs when anti-CD19 CAR T-Cells kill normal B lymphocytes that express CD19. These patients are typically at high risk of developing infections, because of their hypogammaglobulinemia. However, this can be treated with intravenous immunoglobulin (IVIG) replacement therapy.
    • Cytokine Release Syndrome (CRS) – Potentially life-threatening condition that results from the pathologic over-activation of T-Cells. It is an acute systemic inflammatory syndrome characterised by fever and multiple organ dysfunction.
    • Neurotoxicity – Damage to the brain or peripheral nervous system caused by exposure to natural or man-made toxic substances. These toxins can alter the activity of the nervous system in ways that can disrupt or kill nerves.

  • What If The Requirements For CAR T-Cell Immunotherapy Are Not Met?

    • T-Cell Cryopreservation Option
    If any of the above requirements are not met for the patient to be eligible to undergo the CAR T-Cell immunotherapy for the time being, there is an option for the patient to freeze their T- Cells for future use once treatment can proceed.

  • How Long Is The CAR T-Cell Immunotherapy Treatment Process?

    1. Pre-assessment – Up to 4 weeks.
    2. Pre-treatment phase (apheris, CAR T-Cell manufacturing, conditioning chemotherapy) – Up to 6 weeks.
    3. Treatment (CAR T-Cell infusion, monitoring) – Up to 1 week.
    4. Post-treatment Monitoring (follow up) – Up to 24 weeks.
    Disclaimer: The actual immunotherapy treatment process is dependent on individual patients and the type of cancer.

  • https://immunotherapy.life/wp-content/uploads/2021/02/0001-320x454.jpg

    For a more in-depth understanding on
    CAR T-Cell Immunotherapy, we’ve
    prepared a brochure that provides you
    with the information you need.

    For a more in-depth understanding on CAR T-Cell Immunotherapy, we’ve prepared a brochure that provides you with the information you need.

    Have Any Questions About CAR T-Cell
    Immunotherapy That Isn’t Listed On Our FAQ Page?
    Reach Out To Us And We’ll Get In Touch.

    COMPANY

    Sign up for you and your loved ones to receive the latest news and updates about CAR T-Cell Immunotherapy.

      https://immunotherapy.life/wp-content/uploads/2021/02/MGRC-LogoFooter.png
      https://immunotherapy.life/wp-content/uploads/2021/01/MGRC-Logo.png
      https://immunotherapy.life/wp-content/uploads/2021/02/Cyterium-Logo-RGB-02-320x68.png
      https://immunotherapy.life/wp-content/uploads/2021/01/MGRC-Logo.png

      Copyright © 2021 Malaysian Genomics Resource Centre Berhad (652790-V). All Rights Reserved.

      Copyright © 2021 Malaysian Genomics Resource Centre Berhad (652790-V). All Rights Reserved.